Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Sees Large Decline in Short Interest

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 155,235 shares, a decrease of 40.4% from the June 15th total of 260,360 shares. Based on an average daily trading volume, of 252,050 shares, the days-to-cover ratio is currently 0.6 days. Approximately 5.0% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock has an average rating of “Sell”.

Get Valion Bio Inc. Common Stock alerts:

Read Our Latest Stock Report on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Stock Performance

Shares of VBIO opened at $0.45 on Thursday. The company has a current ratio of 3.31, a quick ratio of 3.02 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $0.69 and its two-hundred day simple moving average is $0.93. Valion Bio, Inc. Common Stock has a 12 month low of $0.40 and a 12 month high of $5.60. The stock has a market capitalization of $1.44 million, a P/E ratio of -0.07 and a beta of 1.82.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($2.23) EPS for the quarter.

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.

Featured Articles

• Five stocks we like better than Valion Bio, Inc. Common Stock
• Which Storage Stock Is Best Positioned to Win the AI Memory War?
• Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
• Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
• CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks

Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.